Videos

The assistant professor of medicine at Stanford University highlighted how gastrointestinal dysfunction in Parkinson disease can affect levodopa bioavailability and symptom management. [WATCH TIME: 7 minutes]

The associate professor of psychiatry and human behavior at UC Irvine explored how analyzing specific sleep oscillations may uncover early neurodegenerative changes and guide future therapeutic targets. [WATCH TIME: 4 minutes]

The director of movement disorders at the Banner Sun Health Research Institute discussed distinguishing atypical Parkinsonian disorders early and planning care around their complex symptomatology. [WATCH TIME: 4 minutes]

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai detailed how monitoring tools and neuroprotective approaches are evolving for iRBD as research intensifies on its link to Parkinsonian syndromes. [WATCH TIME: 4 minutes]

The director of the MedStar Georgetown Headache Center explained why data from trials like TEMPLE help strengthen the argument for CGRP therapies as first-line treatments for migraine. [WATCH TIME: 3 minutes]

Neurology News Network. for the week ending July 5, 2025. [WATCH TIME: 4 minutes]

A panelist discusses how dual orexin receptor antagonists (DORAs) offer a novel approach to treating insomnia by reducing wakefulness rather than inducing sedation, highlighting the importance of patient education on their gradual onset, distinct mechanism, and the need for consistent use to achieve long-term benefits.

The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed a complex case of childhood-onset dystonia treated with DBS. [WATCH TIME: 6 minutes]

The director of the MedStar Georgetown Headache Center discussed results from the phase 3 TEMPLE trial, which showed improved tolerability and cognitive outcomes with atogepant vs topiramate in episodic migraine. [WATCH TIME: 5 minutes]

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai explained how his team validated an iRBD actigraphy classifier across new devices and datasets to enhance early, scalable screening for neurodegenerative disease. [WATCH TIME: 5 minutes]

A panelist discusses how DMD progression affects different muscle groups over time, with the most serious complications involving respiratory and cardiac muscles, necessitating specialized care from pulmonologists and cardiologists.

The sleep and stroke neurologist at Barrow Neurological Institute provided insights on the potential of sleep-boosting strategies—including pharmacologic options—to enhance glymphatic clearance and improve stroke recovery outcomes. [WATCH TIME: 4 minutes]

A panelist discusses how ongoing research into next-generation DMD therapies aims to improve delivery methods, develop better vectors that can carry larger dystrophin genes, and determine optimal treatment timing, with evidence suggesting earlier intervention may be more effective.

At ATMRD 2025, a patient advocate living with PD and advisory board member of the Parkinson's Foundation outlined key nonpharmacologic tools that have supported her care journey. [WATCH TIME: 5 minutes]

The neurologist at Christiana Care discussed how focused ultrasound may be emerging as a preferred, less invasive treatment option for essential tremor, especially in older patients with comorbidities. [WATCH TIME: 5 minutes]

The director of the Movement Disorders Clinic at Houston Methodist Hospital discussed the distinct features, progression, and clinical implications of psychosis in Parkinson disease. [WATCH TIME: 4 minutes]

The movement disorder neurologist at University of Rochester Medical Center outlined a 5-pillar model that emphasized holistic care, patient-centered communication, and proactive support in movement disorders. [WATCH TIME: 5 minutes]

The professor of psychology at Avila University discussed how cognitive behavioral therapy and social support can help to improve quality of life for individuals with Parkinson disease. [WATCH TIME: 4 minutes]

The chief program officer at PMD Alliance discussed the value of combining experiential learning and holistic care strategies to support advanced therapeutics in Parkinson disease. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending June 28, 2025. [WATCH TIME: 4 minutes]

A panelist discusses how managing chronic insomnia requires setting realistic patient expectations around gradual improvement, emphasizing consistent effort over time, and using both clinical tools and patient feedback to assess progress toward more restorative sleep.

The medical advisor at Tactical Medical Solutions shared insights from both clinical and personal perspectives on the importance of empathy and active listening in managing Parkinson disease. [WATCH TIME: 3 minutes]

The assistant professor in the Department of Neuroscience at Université de Montréal discussed the importance of weighing the risks of multiple sclerosis against treatment risks, emphasizing individualized care. [WATCH TIME: 4 minutes]

The consultant neurologist at Torbay and Southern Devon Healthcare NHS Foundation Trust discussed the implementation of digital platforms and lifestyle-focused clinics to streamline MS care. [WATCH TIME: 5 minutes]

A panelist discusses how older patients with DMD might benefit from newer genetic therapies including gene therapy and exon skipping, though eligibility depends on specific mutations and absence of pre-existing immunity to AAV vectors.

The chair of neurology at the University of South Carolina discussed findings from a study recently presented at AHS 2025 that linked migraine to autonomic dysfunction, increased risk of atrial fibrillation, and cardioembolic stroke. [WATCH TIME: 5 minutes]

A panelist discusses how a 16-year-old patient with DMD shows more rapid disease progression despite early steroid treatment, with early onset cardiac issues, scoliosis, and increasing upper limb weakness requiring comprehensive specialist care.

The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]

The neurologist and headache specialist at the Montreal Neurological Clinic spoke about a recent national survey presented at AHS 2025 that revealed insightful patient perspectives in migraine. [WATCH TIME: 5 minutes]

The professor of neurology at the Geisel School of Medicine at Dartmouth broke down the FDA approval of STS101, a new DHE nasal powder, and its implications for acute migraine care. [WATCH TIME: 7 minutes]